3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
5
Phase 2
3
Phase 1
3
Phase 1/2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Breast
2
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
210
Cyclophosphamide
122
Nivolumab
109
Carboplatin
92
fludarabine
81
Gemcitabine
76
Specimen Handling
74
Bevacizumab
72
venetoclax
70
Injections
70
Magnetic Resonance Spectroscopy
67
Dexamethasone
66
Paclitaxel
64
Biopsy
59
atezolizumab
56
Cisplatin
53
Ipilimumab
50
Temozolomide
45
Docetaxel
42
Azacitidine
42
Pemetrexed
41
Lenalidomide
41
Oxaliplatin
40
Rituximab
39
Radiotherapy
39
Fluorouracil
39
Cetuximab
37
durvalumab
36
Cytarabine
36
Capecitabine
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
AZD9833
×
1 year
×
Clear all
NCT06188520
2026-05-11
CYCAD-1
AstraZeneca
Phase 1/2
Recruiting
564 enrolled
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled